Literature DB >> 7523160

Modulation of human fibroblast activity by selected angiogenesis inhibitors.

J Wong1, N Wang, J W Miller, J S Schuman.   

Abstract

Tenon's fibroblast (TF) bleb encapsulation is a common cause of filtering surgery failure. Various pharmacologic agents have been used in an attempt to inhibit this response. The effects of three angiogenesis inhibitors were studied. AGM-1470, a fumagillin analog and hydrocortisone 21-phosphate (HC21P) complexed with heparin or with the heparin analog beta-cyclodextrin tetradecasulfate (BCD-TDS) in modulating human tenon's fibroblasts in cell culture. It has been clinically demonstrated that well vascularized blebs are associated with a poorer prognosis. In addition to reducing bleb neovascularization, angiogenesis inhibitors may have an additional therapeutic role in decreasing fibroblast activity. Drug effects were assessed by studying cell growth rates by cell Coulter counting and rate of wound closure. TF's were grown in DMEM with 10% FBS and 1% PCN-strep with fungizone. Angiogenesis inhibitors were added to growth medium in varying concentrations: AGM-1470 alone, HC21P complexed with heparin and HC21P complexed with BCD-TDS. Controls were grown in control medium alone, medium with added ethanol, or with added BCD-TDS, heparin or HC21P. We found a dose related inhibition of cell growth with all of the angiogenesis inhibitor combinations, which was not seen in the control groups. Tenon's fibroblast proliferation was significantly inhibited by AGM-1470 as seen in the four higher concentrations (P < 0.05) with insignificant inhibition at the lowest concentration of AGM-1470 (P = 0.38). The heparin:HC21P and heparin:BCD-TDS combinations demonstrated significant inhibition at all concentrations (P < 0.05). Wound closure was significantly inhibited by all the added agents, except AGM-1470 and the controls. The rate of wound closure was significantly reduced by the highest concentrations of the heparin:HC21P and heparin:BCD-TDS combinations (P < 0.05), although it was not significantly affected by lower concentrations (P > 0.05). Rank order of potencies of these agents for inhibition of TF proliferation was AGM-1470, BCD-TDS:HC21P, heparin:HC21P, HC21P, while the rank order of potencies for these agents for inhibition of wound closure was HC21P, heparin:HC21P, BCD-TDS:HC21P, AGM-1470. These selected angiogenesis inhibitors appear to have marked inhibitory effects on TF proliferation and migration, which may have a potential clinical role in modulating wound healing associated with glaucoma filtering surgery.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523160     DOI: 10.1006/exer.1994.1037

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  11 in total

Review 1.  [Inhibition of angiogenesis in the anterior chamber of the eye].

Authors:  F Bock; Y König; T Dietrich; P Zimmermann; M Baier; C Cursiefen
Journal:  Ophthalmologe       Date:  2007-04       Impact factor: 1.059

2.  Bevacizumab-loaded polyurethane subconjunctival implants: effects on experimental glaucoma filtration surgery.

Authors:  Jayter Silva Paula; Vanessa Raquel Coimbra Ribeiro; Fernando Chahud; Roberta Cannellini; Tassia Cristina Monteiro; Elionai Cassiana de Lima Gomes; Peter Sol Reinach; Maria de Lourdes Veronese Rodrigues; Armando Silva-Cunha
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-07       Impact factor: 2.671

3.  ISRCTN12125882 - Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma - Study Protocol.

Authors:  Frank Bochmann; Claude Kaufmann; Christoph N Becht; Ivo Guber; Michael Kaiser; Lucas M Bachmann; Michael A Thiel
Journal:  BMC Ophthalmol       Date:  2011-01-17       Impact factor: 2.209

4.  Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma.

Authors:  Mohammad-Reza Sedghipour; Ali Mostafaei; Yousef Taghavi
Journal:  Clin Ophthalmol       Date:  2011-06-15

5.  Subconjunctival bevacizumab injection in glaucoma filtering surgery: a case control series.

Authors:  Jing Wang; Paul Harasymowycz
Journal:  ISRN Ophthalmol       Date:  2013-03-14

Review 6.  The Effects of Bevacizumab in Augmenting Trabeculectomy for Glaucoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Xiaoyan Liu; Liang Du; Ni Li
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 7.  Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma.

Authors:  Vanessa Andrés-Guerrero; Lucía Perucho-González; Julián García-Feijoo; Laura Morales-Fernández; Federico Saenz-Francés; Rocío Herrero-Vanrell; Luis Pablo Júlvez; Vicente Polo Llorens; José María Martínez-de-la-Casa; Anastasios-Georgios Konstas
Journal:  Adv Ther       Date:  2016-12-20       Impact factor: 3.845

8.  The Effect of a Triple Combination of Bevacizumab, Sodium Hyaluronate and a Collagen Matrix Implant in a Trabeculectomy Animal Model.

Authors:  Vanessa Andrés-Guerrero; Irene Camacho-Bosca; Liseth Salazar-Quiñones; Nestor Ventura-Abreu; Mercedes Molero-Senosiain; Samuel Hernández-Ruiz; Guillermo Bernal-Sancho; Rocío Herrero-Vanrell; Julián García-Feijóo
Journal:  Pharmaceutics       Date:  2021-06-17       Impact factor: 6.321

Review 9.  Improving patient outcomes following glaucoma surgery: state of the art and future perspectives.

Authors:  Tine Van Bergen; Sarah Van de Velde; Evelien Vandewalle; Lieve Moons; Ingeborg Stalmans
Journal:  Clin Ophthalmol       Date:  2014-05-02

10.  Short-Term Results of Sutureless Scleral Tunnel Trabeculectomy Using Adjunctive Topical Bevacizumab.

Authors:  Mohammad Arish; Omid Bagherzadeh; Seyed Sajad Ahmadi; Javad Sadeghi-Allahabadi; Samira Hassanzadeh
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.